On November 8, 2022,Taysha Gene Therapies, Inc. closed the transaction. The company received $50 million in its final tranche.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.45 USD | +2.51% | -0.41% | +38.42% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,514 JPY | +0.53% | +1.51% | 17.23B | ||
2.45 USD | +2.51% | -0.41% | 458M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.42% | 458M | |
+1.77% | 42.86B | |
+46.62% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.